公开(公告)号：US20240316081A1

公开(公告)日：2024-09-26

申请号：US18676985

申请日：2024-05-29

申请人： Anhui Agricultural University

发明人： Yijun WANG ,  Zhipeng Kan ,  Xiaochun Wan ,  Jinbao Huang ,  Kangyi Zhang ,  Yunqiu Yang ,  Xiaoyu Tang

IPC分类号： A61K31/70

CPC分类号： A61K31/70

摘要： The present disclosure discloses a method for prolonging half-life of theanine in vivo. According to the present disclosure, a specific theanine glycoside compound formed by modification with a specific monosaccharide is used for prolonging the half-life of the theanine in vivo, which can be used for preparing sustained release drugs, prolonging action time of drugs, reducing administration frequency and improving compliance of patients. With the method of the present disclosure, the theanine glycoside compound obtained after modification can have a broad application prospect and a high commercial value in scientific research and clinical application.

公开(公告)号：US20240307425A1

公开(公告)日：2024-09-19

申请号：US18272466

申请日：2021-03-23

申请人： TIANJIN CHASE SUN PHARMACEUTICAL CO., LTD.

发明人： Yang Yu ,  Jianli Wang ,  Chunliang Jiang ,  Xiangcheng Wang ,  Yukun Li ,  Baoqi Li ,  Guiping Zhang ,  Kai Dong ,  Xiaoqing Yao

IPC分类号： A61K31/7048 ,  A61K31/192 ,  A61K31/365 ,  A61K31/70 ,  A61P37/06

CPC分类号： A61K31/7048 ,  A61K31/192 ,  A61K31/365 ,  A61K31/70 ,  A61P37/06

摘要： The present disclosure provides a pharmaceutical composition for treating sepsis and use thereof, belonging to the technical field of chemical drugs. The present disclosure provides a three-component pharmaceutical composition including hydroxysafflower yellow A (HSYA), paeoniflorin, and albiflorin. The present disclosure further provides a seven-component pharmaceutical composition including HSYA, paeoniflorin, albiflorin, oxypaeoniflorin, senkyunolide I, salvianic acid A sodium (SAAS), and ferulic acid. In the present disclosure, it is verified at the cell level and the animal level that both two groups of the pharmaceutical compositions have an efficacy of effectively treating sepsis. Meanwhile, drug toxicity experiments show that the two groups of the pharmaceutical compositions both are safe. The pharmaceutical composition is an active ingredient of the Xuebijing Injection, which can be used for the clinical treatment of sepsis.

公开(公告)号：US12012598B2

公开(公告)日：2024-06-18

申请号：US16324955

申请日：2017-08-14

申请人： TOOLGEN INCORPORATED

发明人： Seok Joong Kim ,  Yoon-Young Kim ,  Ho-Sung Yu ,  In-Young Jung ,  Jung Min Lee

IPC分类号： C12N15/113 ,  A61K35/14 ,  C07K1/00 ,  C07K14/705 ,  C12N5/0783 ,  C12N5/0784 ,  C12N15/10 ,  C12N15/52 ,  C12N15/63 ,  C12N15/85 ,  A61K31/70 ,  C12N9/22

CPC分类号： C12N15/1132 ,  A61K35/14 ,  C07K14/70503 ,  C07K14/70564 ,  C07K14/70575 ,  C07K14/70578 ,  C07K14/70596 ,  C12N5/0637 ,  C12N5/0638 ,  C12N5/064 ,  C12N5/0646 ,  C12N15/102 ,  C12N15/1138 ,  C12N15/52 ,  C12N15/63 ,  C12N15/85 ,  C12N9/22 ,  C12N2310/20 ,  C12N2320/30 ,  Y02A50/30

摘要： The present invention relates to an artificially manipulated immune system having an improved immune effect. More particularly, the present invention relates to an immune system having functions artificially altered which comprises artificially manipulated immunoregulatory elements and cells containing the same. Contemplated according to a particular embodiment is an immune system comprising artificially manipulated immunoregulatory genes such as PD-1, CTLA-4, A20, DGKα, DGKζ, FAS, EGR2, PPP2R2D, PSGL-1, KDM6A, and TET2, and/or expression products thereof.

公开(公告)号：US11975121B2

公开(公告)日：2024-05-07

申请号：US17083267

申请日：2020-10-28

申请人： PETVIVO HOLDINGS, INC.

发明人： David B. Masters ,  Eric P. Berg

IPC分类号： A61K31/726 ,  A61K8/64 ,  A61K8/65 ,  A61K31/70 ,  A61K31/715 ,  A61K31/727 ,  A61K31/728 ,  A61K35/545 ,  A61K38/39 ,  A61K45/06 ,  A61L27/20 ,  A61L27/22 ,  A61L27/24 ,  A61L27/34 ,  A61L27/48 ,  A61L27/50 ,  A61L31/10 ,  A61L33/12 ,  A61Q19/08 ,  A61K38/00 ,  A61M25/00

CPC分类号： A61L27/24 ,  A61K8/64 ,  A61K8/65 ,  A61K31/70 ,  A61K31/715 ,  A61K31/726 ,  A61K31/727 ,  A61K31/728 ,  A61K35/545 ,  A61K38/39 ,  A61K45/06 ,  A61L27/20 ,  A61L27/22 ,  A61L27/227 ,  A61L27/34 ,  A61L27/48 ,  A61L27/507 ,  A61L31/10 ,  A61L33/12 ,  A61Q19/08 ,  A61K38/00 ,  A61K2800/91 ,  A61M25/0045 ,  A61L27/34 ,  C08L89/00 ,  A61L27/48 ,  C08L89/00 ,  A61L31/10 ,  C08L89/00 ,  A61L27/20 ,  C08L5/00

摘要： The present invention relates to protein biocoacervates and biomaterials and the methods of making and using protein biocoacervates and biomaterials. More specifically the present invention relates to protein biocoacervates and biomaterials that may be utilized for various medical applications including, but not limited to, drug delivery devices for the controlled release of pharmacologically active agents, coated medical devices (e.g. stents, valves . . . ), vessels, tubular grafts, vascular grafts, wound healing devices including protein suture biomaterials and biomeshes, dental plugs and implants, skin/bone/tissue grafts, tissue fillers, protein biomaterial adhesion prevention barriers, cell scaffolding and other biocompatible biocoacervate or biomaterial devices.

公开(公告)号：US11963973B2

公开(公告)日：2024-04-23

申请号：US17427542

申请日：2020-02-03

申请人： HEMISPHERIAN AS

发明人： Adam Brian Robertson ,  Terezia Prikrylova

IPC分类号： A01N43/04 ,  A61K31/17 ,  A61K31/495 ,  A61K31/513 ,  A61K31/70 ,  A61K31/7068 ,  A61K31/7072 ,  A61P35/00 ,  C07H19/06 ,  C07H19/10

CPC分类号： A61K31/7072 ,  A61K31/17 ,  A61K31/495 ,  A61K31/513 ,  A61K31/7068 ,  A61P35/00 ,  C07H19/06 ,  C07H19/10

摘要： The present invention relates to a compound of Formula (I), or a stereoisomer, solvate, tautomer or pharmaceutically acceptable salt thereof, wherein X, W1, W2, Y, Z, R1, R2 and R3 are as defined in the disclosure herein, for use in therapy, particularly for use in the treatment of cancer. The present invention also relates to methods of treating cancer comprising the administration of a compound of Formula (I) to a subject in need thereof, and to pharmaceutical compositions and kits comprising such compounds.

公开(公告)号：US11918599B2

公开(公告)日：2024-03-05

申请号：US18047392

申请日：2022-10-18

申请人： GliaCellTech Inc. ,  Daegu Gyeongbuk Institute of Science and Technology

发明人： Seong-Woon Yu ,  Hyeri Nam ,  Younghwan Lee

IPC分类号： A01N43/04 ,  A61K31/70 ,  A61K31/7068 ,  A61P25/28 ,  A61P29/00

CPC分类号： A61K31/7068 ,  A61P25/28 ,  A61P29/00

摘要： The present invention relates to a composition for preventing or treating a neuroinflammatory disease, which can inhibit the expression of neuroinflammatory cytokines, promote the degradation of amyloid beta, and improve a cognitive function in an animal model of Alzheimer's disease. More specifically, the present invention relates to a composition for preventing or treating a neuroinflammatory disease comprising didanosine or a pharmaceutically acceptable salt thereof, and the composition may be used for the development of drugs and quasi-drug materials.

公开(公告)号：US11873319B2

公开(公告)日：2024-01-16

申请号：US17464494

申请日：2021-09-01

申请人： The Regents of the University of California

发明人： Russell E. Vance ,  Ming C. Hammond ,  Dara Burdette ,  Elie J. Diner ,  Stephen C. Wilson

IPC分类号： A01N43/04 ,  A61K31/70 ,  C07H21/02 ,  A61K31/7084

CPC分类号： C07H21/02 ,  A61K31/7084

摘要： Methods and compositions are provided for increasing the production of a type I interferon (IFN) in a cell. Aspects of the methods include increasing the level of a 2′-5′ phosphodiester linkage comprising cyclic-di-nucleotide in a cell in a manner sufficient to increase production of the type I interferon (IFN) by the cell. Also provided are compositions and kits for practicing the embodiments of the methods.

公开(公告)号：US20230404961A1

公开(公告)日：2023-12-21

申请号：US18187165

申请日：2023-03-21

申请人： Allergan, Inc.

发明人： Joseph G. Vehige ,  Peter A. Simmons ,  Joan-En Chang-Lin

IPC分类号： A61K31/205 ,  A61K9/08 ,  A61K47/26 ,  A61K47/38 ,  A61K9/00 ,  A61K31/047 ,  A61K31/14 ,  A61K31/717 ,  A61K31/728 ,  A61K38/17 ,  A61K31/70 ,  A61K47/02

CPC分类号： A61K31/205 ,  A61K9/08 ,  A61K47/26 ,  A61K47/38 ,  A61K9/0048 ,  A61K31/047 ,  A61K31/14 ,  A61K31/717 ,  A61K31/728 ,  A61K38/1732 ,  A61K31/70 ,  A61K47/02

摘要： Ophthalmic compositions including compatible solute components and/or polyanionic components are useful in treating eyes, for example, to relieve dry eye syndrome, to protect the eyes against hypertonic insult and/or the adverse effects of cationic species on the ocular surfaces of eyes and/or to facilitate recovery from eye surgery.

公开(公告)号：US11826476B2

公开(公告)日：2023-11-28

申请号：US16676395

申请日：2019-11-06

申请人： ORBIS HEALTH SOLUTIONS, LLC

发明人： Thomas E. Wagner ,  George E. Peoples, Jr.

IPC分类号： A61K39/00 ,  A61K9/50 ,  A61K31/70 ,  A61K31/7088 ,  C12N1/16 ,  A61K9/19 ,  A61K39/39

CPC分类号： A61K9/5068 ,  A61K9/19 ,  A61K31/70 ,  A61K31/7088 ,  A61K39/0011 ,  A61K39/39 ,  C12N1/16 ,  A61K2039/5154 ,  A61K2039/55561 ,  A61K2039/55572 ,  A61K2039/55588 ,  A61K2039/60

摘要： The present invention generally relates to compositions and methods for delivering a vaccine. The compositions and methods disclosed herein are particularly useful in making prophylactic and therapeutic vaccines.

公开(公告)号：US11817195B2

公开(公告)日：2023-11-14

申请号：US17938310

申请日：2022-10-05

申请人： AstraZeneca UK Limited

发明人： Robert Peter Prybolsky ,  Judy Firor

IPC分类号： G16H10/20 ,  G16H10/40 ,  G16H20/13 ,  G16H10/60 ,  G16H70/40 ,  A61K31/70

CPC分类号： G16H20/13 ,  A61K31/70 ,  G16H10/20 ,  G16H10/40 ,  G16H10/60 ,  G16H70/40

摘要： A method is provided for lowering blood sugar in a subject in need thereof by administering a gliflozin Sodium-Glucose Cotransport 2 inhibitor pharmaceutical composition to a subject qualified for over-the-counter access to the gliflozin Sodium-Glucose Cotransport 2 inhibitor pharmaceutical composition. In some embodiments, the gliflozin Sodium-Glucose Cotransport 2 inhibitor pharmaceutical composition includes empagliflozin, canagliflozin, and ertugliflozin. In some embodiments, the gliflozin Sodium-Glucose Cotransport 2 inhibitor pharmaceutical composition includes (2S,3R,4R,5S,6R)-2-[4-chloro-3-[(4-ethoxyphenyl)methyl]phenyl]-6-(hydroxymethyl)oxane-3,4,5-triol or a pharmaceutically acceptable salt thereof.